Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status

[1]  A. Churg,et al.  CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations , 2021, Virchows Archiv.

[2]  A. Churg,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2020, The American journal of surgical pathology.

[3]  L. Chirieac,et al.  Molecular characterization of diffuse malignant peritoneal mesothelioma , 2020, Modern Pathology.

[4]  M. Balancin,et al.  Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas , 2020, Pathobiology.

[5]  D. Huntsman,et al.  Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status , 2020, Modern Pathology.

[6]  S. Imbeaud,et al.  Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival , 2020, Molecular oncology.

[7]  R. Schmid,et al.  Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma , 2020, Therapeutic advances in medical oncology.

[8]  F. Cappuzzo,et al.  Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study , 2019, Cancers.

[9]  S. Ganesan,et al.  Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. , 2018, Cancer treatment and research communications.

[10]  A. Churg,et al.  Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions. , 2020, Archives of pathology & laboratory medicine.

[11]  M. Köbel,et al.  p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.

[12]  M. Köbel,et al.  Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  David L. Gibbs,et al.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma. , 2018, Cancer discovery.

[14]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[15]  N. Rosenfeld,et al.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.

[16]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[18]  K. Schmid,et al.  Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. , 2014, Future oncology.

[19]  F. Galateau-Sallé,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2000, Archives of pathology & laboratory medicine.

[20]  A. Reuss,et al.  The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.

[21]  Claire W Michael,et al.  The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions , 2010, Cancer cytopathology.

[22]  P. Hasleton,et al.  Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports , 2006, Histopathology.

[23]  R. Attanoos,et al.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 , 2003, Histopathology.

[24]  I. Downie,et al.  Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.

[25]  A. Nicholson,et al.  The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis , 1999, The Journal of pathology.

[26]  V. Roggli,et al.  The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. , 1998, American journal of clinical pathology.

[27]  A. Giordano,et al.  p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. , 1997, Anticancer research.

[28]  P. Cagle,et al.  p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. , 1994, Human pathology.

[29]  A. Gibbs,et al.  p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[30]  E. van Marck,et al.  Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium , 1992, The Journal of pathology.

[31]  N. Shepherd,et al.  p53 expression is common in malignant mesothelioma , 1992, Histopathology.